Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at 2025 San Antonio Breast Cancer Symposium
New data will be presented about Precise® Molecular Residual Disease (MRD) Test and MyRisk® Hereditary Cancer Test
SALT LAKE CITY, Dec. 09, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will present new data in eight abstracts at the ® (SABCS).
The company will share the latest advances in the that support guideline-driven treatment decisions. Additionally, the company is presenting data on its , an ultrasensitive, second-generation pan-tumor MRD test that is especially impactful for low-tumor-shedding cancers, such as breast cancer. It has high sensitivity and specificity at low tumor fraction.1
“I am thrilled that we are sharing some very strong data at SABCS from multiple breast-cancer studies that used Precise MRD,” said Dale Muzzey, PhD, Chief Scientific Officer, Myriad Genetics. “Each study showcases the benefit of ultrasensitive and quantitative ctDNA testing, as we observed noteworthy correspondence with clinical outcomes of interest. I’m also pleased that, in addition to MRD studies, we are sharing data about germline testing, somatic testing, and polygenic risk assessment, all areas of excellence for Myriad that underscore our commitment to serving the cancer care continuum.”
Myriad will sponsor a session at the Product Theater, where Gregory Vidal, MD, PhD, associate professor at the University of Tennessee Health Science Center, and Sara Mokhtary-Myers, MS, CGC, certified genetic counselor and Genetics Program Coordinator at Texas Oncology, will discuss the evolving role of tumor genomic and germline testing in breast cancer care. The session will be held on Wednesday, Dec. 10, 2:30–3:30 p.m.
Myriad Genetics Presentations
Personalized Whole-Genome-Based ctDNA Dynamics During Neoadjuvant Therapy Across Breast Cancer Subtypes: Early Insights From MONITOR-Breast
Abstract #3552, Presentation # PS1-13-11
Wednesday, Dec. 10, 12:30-2:00 pm (CST), Exhibit Hall
Presenter: Julia Foldi, MD, PhD, University of Pittsburgh Medical Center
Ultra-sensitive Molecular Residual Disease Detection in Breast Cancer Using Whole-Genome Sequencing-Based Personalized ctDNA Panels: Preliminary Results from the MONSTAR-SCREEN-3 Project
Presentation # PS2-09-07
Wednesday, Dec. 10, 5:00-6:30 pm (CST), Exhibit Hall
Presenter: Yoichi Naito, National Cancer Center Hospital East, Kashiwa, Japan
Ultrasensitive ctDNA-based MRD monitoring predicts relapse in postoperative HR+ inflammatory breast cancer
Abstract #1012, Presentation # PS4-02-02
Thursday, Dec. 11, 5:00-6:30 pm (CST), Exhibit Hall
Presenter: Ranjan Upadhyay MD, PhD, Anderson Cancer Center
Ancestry-specific prevalence of pathogenic variants among patients with breast cancer who do not meet guidelines for genetic testing
Abstract #858, Presentation #PS3-02-30
Thursday, Dec. 11, 12:30-2:00 pm (CST), Exhibit Hall
Presenter: Timothy Simmons, PhD, Biostatistician III, Myriad Genetics
Enhancing breast cancer risk assessment in a community imaging center to identify high-risk patients and guide screening and management
Abstract #202, Presentation # PS3-02-13
Thursday, Dec. 11, 12:30-2:00 pm (CST), Exhibit Hall
Presenter: Tammy McKamie, MSN, RN, ACGN, OCN, Myriad Genetics
Interactions between polygenic variants and clinical factors as predictors of breast cancer risk in women of self-reported Black/African ancestry
Abstract #1222, Presentation # PS3-01-03
Thursday, Dec. 11, 12:30-2:00 pm (CST), Exhibit Hall
Presenter: Timothy Simmons, PhD, Biostatistician III, Myriad Genetics
Co-occurring pathogenic variants in patients with breast cancer
Abstract #1570, Presentation # PS3-02-07
Thursday, Dec. 11, 12:30-2:00 pm (CST), Exhibit Hall
Presenter: Kallie Woods, MS, CGC, Myriad Genetics
Tumor genomic profiling results in breast cancer patients: A comprehensive analysis from a laboratory research registry
Abstract #888, Presentation # PS2-10-26
Wednesday, Dec. 10, 5:00-6:30 pm (CST), Exhibit Hall
Presenter: Gregory Vidal MD, PhD, West Cancer Center and Regional One Health
Myriad Genetics at Booth 1414
In addition to data presentations, Myriad will welcome attendees to its booth (#1414) during exhibition hours. Among the Myriad products highlighted in the company’s 2025 SABCS exhibit are:
- is a tumor-informed assay that uses whole genome sequencing (WGS) to achieve ultra-sensitivity. This unique assay enables the custom selection of up to 1,000 targeted variants for deep analysis. It has impressive limits of detection and sensitivity.1 The test can be used to monitor circulating tumor DNA (ctDNA) levels throughout a patient’s clinical cancer care, starting immediately after diagnosis and continuing through treatment and surveillance. This test is currently available for research use only (RUO) and not available for clinical use.
- is a leading hereditary cancer test that has been expanded to include genes referenced in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)2 and guidelines from American Society of Clinical Oncology (ASCO). These genes are associated with cancer risk and may have clear clinical actionability, supporting the goal that each addition to the panel provides meaningful insights for patient care. The updated MyRisk panel now includes 63 carefully selected genes across more than 11 cancer types, reflecting Myriad’s commitment to meeting evolving clinical needs and delivering clinical value at every step of the cancer care continuum.
- combines genetics, clinical factors (Tyrer-Cuzick), and polygenic risk to uncover insights that gene testing alone may not provide, helping offer more information to support patient decisions in breast cancer risk assessment and management.
- is the only FDA-approved homologous recombination deficiency (HRD) test specifically mentioned in ASCO guidelines for selecting patients with ovarian cancer who may benefit from PARP inhibitors.3 By determining comprehensive HRD status, the MyChoice CDx Test helps expand access to targeted therapy in both early and late-line settings.
1 Acevedo, A. et al. . Poster presented at the San Antonio Breast Cancer Symposium (SABCS) Dec 10-13, 2024.
2 NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
3 Tew WP, Lacchetti C, Birrer MJ, et al. PARP inhibitors in the management of ovarian cancer: ASCO guideline. J Clin Oncol. 2020;38(30):3468-3493
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit .
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including the company’s expectation that, in addition to MRD studies, it will share data about germline testing, somatic testing, and polygenic risk assessment, which are areas of excellence for the company that underscore its commitment to serving the cancer care continuum, and the company’s belief that the expansion of the MyRisk Hereditary Cancer Test to include genes referenced in NCCN Guidelines and guidelines from ASCO will support the company’s goal that each addition to the panel provides meaningful insights for patient care and reflects the company’s commitment to meeting evolving clinical needs and delivering value across the cancer care continuum. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 28, 2025, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.
Investor Contact
Matt Scalo
(801) 584-3532
Media Contact
Kate Schraml
(224) 875-4493
